SecBot SecBot
6-K ·Filed Nov 3, 2026

FMS

Fresenius Medical Care AG
BEARISH
Impact 5/10
Horizonweeks Processed13d 19h ago SEC0001104659-26-121625
6-K: Earnings release
Actionable Insight ▼ Bearish

The narrowed FY 2026 operating income outlook to flat/negative mid-single-digit growth signals continued headwinds from TDAPA regulations and inflation. Monitor Q4 results for the full-year exit rate and any further guidance revision. The 5008X CAREsystem rollout and FME25+ savings program are positive offsets but not yet sufficient to reverse the earnings decline.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$21.73
T+0 close · Nov 3, 2026 · via day close
Latest settled
+4.65%
T+5 · $22.74 · next T+20 in 15d
Vs SPY
+5.24%
α at T+5
Latest observation
+2.10%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $21.73entry
  2. T+1 · 13d ago +6.72%α +5.07% · $23.19
  3. T+5 · 7d ago +4.65%α +5.24% · $22.74
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Fresenius Medical Care reported Q3 2026 revenue of EUR 4,937M (+1% YoY, -1% constant currency) and adjusted EPS (excl. special items) of EUR 1.11, flat YoY. Reported GAAP EPS fell 35% to EUR 0.61 due to EUR 108M in one-time China restructuring charges. The company narrowed its full-year 2026 operating income outlook to between flat and a negative mid-single-digit percent growth rate, citing regulatory headwinds and inflation.

Key Financial Metrics

EPS (Adj.)
$1.11
GAAP: $0.61
Revenue
$4.9B
est $4.9B · +0.6% · +1.1% YoY
Guidance
broadly flat
lowered
Free Cash Flow
$564.0M

Key Facts

  • Q3 2026 revenue EUR 4,937M, +1% YoY reported, -1% constant currency
  • Reported GAAP EPS EUR 0.61, -35% YoY; adjusted EPS EUR 1.11, flat YoY
  • Reported operating income EUR 384M, -19% YoY; adjusted operating income EUR 545M, -5% YoY
  • Reported net income EUR 160M, -42% YoY; adjusted net income EUR 291M, -10% YoY
  • China strategy refinement caused EUR 108M one-time costs (impairments, scrappage, termination)
  • FY 2026 operating income outlook narrowed to flat to negative mid-single-digit percent growth (from prior range)
  • Revenue outlook unchanged at broadly flat for FY 2026
  • U.S. same-market treatment growth -1.1% in Q3; international same-market treatment growth +1.4%
  • Operating cash flow EUR 798M, +8% YoY; free cash flow EUR 564M, +3% YoY
  • Net leverage ratio stable at 2.6x, within 2.5x-3.0x target band
  • Share buyback: 9.1M shares (3.4% of total) repurchased for EUR 357M as of Sep 30
  • 5008X CAREsystem rollout: 348 U.S. clinics converted, 1.3M treatments performed

Financial Impact

EUR 108M one-time China restructuring charges; adjusted operating income margin declined 70 bps to 11.0%

revenueepsoperating incomenet incomeoperating margin

Segment Breakdown

SegmentRevenueGrowth
Care Delivery$3.5B+2.7%
Value-Based Care$537.0M-6.8%
Care Enablement$1.5B+6.7%

Risk Factors

  • TDAPA reimbursement regulations continue to pressure U.S. Care Delivery revenue
  • China strategy refinement may lead to further charges or revenue loss
  • U.S. same-market treatment growth negative at -1.1%, indicating patient volume decline
  • Currency headwinds (EUR strength) negatively impacted reported revenue and earnings
  • Inflationary cost increases, especially labor, are pressuring margins

Market Snapshot

Exchange
OTC
Sector
Services-Misc Health & Allied Services, NEC
Analyst Consensus
21% bullish (29 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001104659-26-121625
Document: tm2628784d1_ex99-2.htm0001104659-26-121625
Document: tm2628784d1_6k.htm0001104659-26-121625
Document: 0001104659-26-121625-index-headers.html0001104659-26-121625
Document: 0001104659-26-121625-index.html0001104659-26-121625
Document: 0001104659-26-121625.txt0001104659-26-121625
Earnings Context (Synthetic; results releases only)0001104659-26-121625

Track record

16 reports on FMS

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +3.43% at T+60 after the Apr 7, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13D/A Bearish 5/10 Entry $22.03 Now $21.86 +0.77% settles Nov 20
  2. Nov 9, 20267d ago 6-K Neutral 2/10 Entry $22.95 to $21.86 Now $21.86 −4.75% ▼ −4.75% −3.06% vs SPY
  3. Nov 3, 202613d ago 6-K Bearish 6/10 No price data
  4. Nov 3, 202613d ago 6-K Bearish 5/10 Viewing Entry $21.73 to $22.74 Now $21.86 −0.60% ▼ −4.65% −5.24% vs SPY
  5. Oct 30, 202618d ago Court Ruling Neutral 4/10 Entry $22.61 to $22.95 Now $21.86 −3.32% ▲ +1.50% +1.43% vs SPY
  6. Oct 7, 20265w ago 6-K Neutral 3/10 Entry $20.69 to $21.54 Now $21.86 +5.65% ▲ +4.11% +5.09% vs SPY
  7. Sep 25, 20267w ago 6-K Bearish 5/10 Entry $22.69 to $22.25 Now $21.86 +3.66% ▲ +1.94% +1.72% vs SPY
  8. Sep 1, 202611w ago Court Ruling Neutral 1/10 Entry $22.65 to $22.23 Now $21.86 −3.49% ▼ −1.85% −0.90% vs SPY
  9. Aug 31, 202611w ago GOVT-CONTRACT Neutral 3/10 Entry $22.74 to $22.33 Now $21.86 −3.87% ▼ −1.80% −1.88% vs SPY
  10. Aug 31, 202611w ago Court Ruling Neutral 4/10 Entry $22.74 to $22.33 Now $21.86 −3.87% ▼ −1.80% −1.88% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 5h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026